Imagion Biosystems is pleased to provide an update on its capital management and progress towards its first-in-human study,
Read the Investor Update.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance